Recently, therapeutic synergy for combination of CDK4/6i and PARPi has been demonstrated in various solid tumors, including those of the breast, ovarian, and pancreas [22,23,48], which provides a promising approach for treatment of these cancers regardless HR status. The gene discussed is CDK4; the disease is cancer.